Table 1 Clinical characteristics of the HyperGEN study sample
From: Diastolic wall strain: a simple marker of abnormal cardiac mechanics
Characteristic | All HyperGEN participants (N = 1907) |
|---|---|
Age, y | 51 ± 14 |
Female, n (%) | 1129 (59) |
Ethnicity, n (%) | |
● White | 1032 (54) |
● African-American | 867 (45) |
● Other | 7 (1) |
Recruiting center, n (%) | |
● Birmingham, Alabama | 531 (28) |
● Minneapolis, Minnesota | 376 (20) |
● Forsyth County, North Carolina | 537 (28) |
● Salt Lake City, Utah | 463 (24) |
Comorbidities, n (%) | |
● Hypertension | 1085 (57) |
● Obesity | 897 (47) |
● Diabetes mellitus | 314 (16) |
● Chronic kidney disease | 158 (8) |
● Myocardial infarction | 83 (4) |
● Transient ischemic attack or stroke | 77 (4) |
Medications, n (%) | |
● Anti-hypertensive medication | 950 (50) |
● Angiotensin-converting enzyme inhibitor | 381 (20) |
● Angiotensin receptor blocker | 51 (3) |
● Alpha blocker | 145 (8) |
● Beta-blocker | 245 (13) |
● Calcium channel blocker | 417 (22) |
● Loop diuretic | 108 (6) |
● Thiazide diuretic | 244 (13) |
● Oral hypoglycemic | 195 (10) |
● Insulin | 69 (4) |
● Lipid lowering medication | 163 (9) |
● Statin | 144 (8) |
Physical examination: | |
● Systolic blood pressure, mm Hg | 126 ± 20 |
● Diastolic blood pressure, mm Hg | 72 ± 11 |
● Body mass index, kg/m2 | 31 ± 7 |
● Waist circumference, cm | 102 ± 16 |
Laboratory data: | |
● Sodium, mEq/L | 142 ± 2 |
● Creatinine, mg/dl | 0.97 ± 0.28 |
● Estimated glomerular filtration rate, ml/min/1.73 m2 | 85 ± 20 |
● Fasting glucose, mg/dl | 105 ± 43 |
● Total serum cholesterol, mg/dl | 197 ± 39 |
● High density lipoprotein, mg/dl | 51 ± 15 |
● Low density lipoprotein, mg/dl | 119 ± 34 |